These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22341206)

  • 1. Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry.
    Mekinian A; Ravaud P; Larroche C; Hachulla E; Gombert B; Blanchard-Delaunay C; Cantagrel A; Fain O; Sibilia J; Gottenberg JE; Mariette X;
    Clin Exp Rheumatol; 2012; 30(2):208-12. PubMed ID: 22341206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.
    Mekinian A; Ravaud P; Hatron PY; Larroche C; Leone J; Gombert B; Hamidou M; Cantagrel A; Marcelli C; Rist S; Breban M; Launay D; Fain O; Gottenberg JE; Mariette X
    Ann Rheum Dis; 2012 Jan; 71(1):84-7. PubMed ID: 21926185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
    Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
    Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome.
    Devauchelle-Pensec V; Morvan J; Rat AC; Jousse-Joulin S; Pennec Y; Pers JO; Jamin C; Renaudineau Y; Quintin-Roué I; Cochener B; Youinou P; Saraux A
    Clin Exp Rheumatol; 2011; 29(1):6-12. PubMed ID: 21345287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral and central nervous system involvement in a patient with primary Sjögren's syndrome: a case report.
    Ging K; Mono ML; Sturzenegger M; Zbinden M; Adler S; Genitsch V; Wagner F
    J Med Case Rep; 2019 May; 13(1):165. PubMed ID: 31126347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Sjogren's syndrome with central nervous system involvement.
    Alhomoud IA; Bohlega SA; Alkawi MZ; Alsemari AM; Omer SM; Alsenani FM
    Saudi Med J; 2009 Aug; 30(8):1067-72. PubMed ID: 19668890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adolescent Sjogren's syndrome presenting as psychosis: a case series.
    Hammett EK; Fernandez-Carbonell C; Crayne C; Boneparth A; Cron RQ; Radhakrishna SM
    Pediatr Rheumatol Online J; 2020 Feb; 18(1):15. PubMed ID: 32046763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
    Nikiphorou E; Hall FC
    Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401
    [No Abstract]   [Full Text] [Related]  

  • 11. Sustained response to rituximab in a patient with Sjögren´s syndrome and severe refractory polyneuropathy.
    Pertovaara M; Korpela M
    Clin Exp Rheumatol; 2012; 30(5):808; author reply 809. PubMed ID: 22992382
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
    Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S
    Front Immunol; 2019; 10():1527. PubMed ID: 31354708
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab therapy in primary Sjögren's syndrome with interstitial lung disease: a retrospective cohort study.
    Chen MH; Chen CK; Chou HP; Chen MH; Tsai CY; Chang DM
    Clin Exp Rheumatol; 2016; 34(6):1077-1084. PubMed ID: 27607895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome.
    Jousse-Joulin S; Devauchelle-Pensec V; Cornec D; Marhadour T; Bressollette L; Gestin S; Pers JO; Nowak E; Saraux A
    Arthritis Rheumatol; 2015 Jun; 67(6):1623-8. PubMed ID: 25708147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment approaches in primary Sjogren syndrome.
    Vissink A; Kallenberg CG; Bootsma H
    JAMA; 2010 Nov; 304(18):2015-6; author reply 2016. PubMed ID: 21063008
    [No Abstract]   [Full Text] [Related]  

  • 17. Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.
    Lehner GF; Brunner-Palka M; Rettenbacher T; Schmidauer R; Herold M
    Rheumatology (Oxford); 2014 Jul; 53(7):1349-50. PubMed ID: 24446469
    [No Abstract]   [Full Text] [Related]  

  • 18. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients.
    Delalande S; de Seze J; Fauchais AL; Hachulla E; Stojkovic T; Ferriby D; Dubucquoi S; Pruvo JP; Vermersch P; Hatron PY
    Medicine (Baltimore); 2004 Sep; 83(5):280-291. PubMed ID: 15342972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
    Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
    Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical fatigue characterises patient experience of primary Sjögren's syndrome.
    Arends S; Meiners PM; Moerman RV; Kroese FG; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Clin Exp Rheumatol; 2017; 35(2):255-261. PubMed ID: 28032845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.